Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Refractory Autoimmune Cytopenias Treated With Venetoclax.

Gordon MJ, Maldonado E, Danilov AV.

Hemasphere. 2019 Jun 4;3(3):e202. doi: 10.1097/HS9.0000000000000202. eCollection 2019 Jun. No abstract available.

2.

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Böttcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG.

Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.

PMID:
27178240
3.

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, Enschede SH, Leverson JD, Ross JA, Maciag PC, Verdugo M, Touzeau C.

Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.

PMID:
29018077
4.

A Concise Review of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia.

Tsang M, Parikh SA.

Curr Hematol Malig Rep. 2017 Feb;12(1):29-38. doi: 10.1007/s11899-017-0366-1. Review.

5.

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, Touzeau C, Punnoose EA, Cordero J, Munasinghe W, Jia J, Salem AH, Freise KJ, Leverson JD, Enschede SH, Ross JA, Maciag PC, Verdugo M, Harrison SJ.

Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.

PMID:
28847998
6.

Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.

Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT.

Blood. 2016 Jan 7;127(1):17-28. doi: 10.1182/blood-2015-07-657981. Epub 2015 Oct 26.

7.
8.

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC.

Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.

9.

[Primary immunodeficiencies presenting with autoimmune cytopenias in adults].

Sève P, Broussolle C, Pavic M.

Rev Med Interne. 2013 Mar;34(3):148-53. doi: 10.1016/j.revmed.2012.05.007. Epub 2012 Jun 15. Review. French.

PMID:
22703729
10.

Mycophenolate mofetil and Sirolimus as second or further line treatment in children with chronic refractory Primitive or Secondary Autoimmune Cytopenias: a single centre experience.

Miano M, Scalzone M, Perri K, Palmisani E, Caviglia I, Micalizzi C, Svahn J, Calvillo M, Banov L, Terranova P, Lanza T, Dufour C, Fioredda F.

Br J Haematol. 2015 Oct;171(2):247-253. doi: 10.1111/bjh.13533. Epub 2015 Jun 8.

PMID:
26058843
11.

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Huemer F, Melchardt T, Jansko B, Wahida A, Jilg S, Jost PJ, Klieser E, Steiger K, Magnes T, Pleyer L, Greil-Ressler S, Rass C, Greil R, Egle A.

Eur J Haematol. 2019 May;102(5):437-441. doi: 10.1111/ejh.13218. Epub 2019 Feb 28.

12.

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW.

Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.

13.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C.

Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.

14.

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, Verdugo M, Lash-Fleming L, Zwaan CM, Vormoor J.

Future Oncol. 2018 Sep;14(21):2115-2129. doi: 10.2217/fon-2018-0121. Epub 2018 Mar 29.

15.

Treatment Outcomes of Novel Targeted Agents in Relapse/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-Analysis.

Chen PH, Ho CL, Lin C, Wu YY, Huang TC, Tu YK, Lee CH.

J Clin Med. 2019 May 23;8(5). pii: E737. doi: 10.3390/jcm8050737.

16.

Use of Sirolimus (Rapamycin) for Treatment of Cytopenias and Lymphoproliferation Linked to Autoimmune Lymphoproliferative Syndrome (ALPS). Two Case Reports.

Cayrol J, Garrido Colino C.

J Pediatr Hematol Oncol. 2017 May;39(4):e187-e190. doi: 10.1097/MPH.0000000000000785.

PMID:
28234735
17.

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.

Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, Salem AH.

Hematol Oncol. 2017 Dec;35(4):679-684. doi: 10.1002/hon.2373. Epub 2016 Dec 16.

PMID:
27982454
18.

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP.

N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.

19.

Acquired immune cytopenias post-cardiac transplantation respond to rituximab.

Tubman VN, Smoot L, Heeney MM.

Pediatr Blood Cancer. 2007 Mar;48(3):339-44.

PMID:
16435382
20.

Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.

Hughes ME, Landsburg DJ, Rubin DJ, Schuster SJ, Svoboda J, Gerson JN, Namoglu E, Nasta SD.

Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):791-798. doi: 10.1016/j.clml.2019.09.612. Epub 2019 Sep 28.

PMID:
31648953

Supplemental Content

Support Center